• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

25.75 -2.15 (-7.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
October 01, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
September 24, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
September 22, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
September 14, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 09, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
August 25, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
July 30, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
June 05, 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
June 02, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Joins the Euronext Tech Leaders Index
June 02, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Closing of Global Offering
May 26, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
May 21, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
May 21, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
May 21, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Launch of Global Follow-On Offering
May 20, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 17, 2026
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 04, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
April 07, 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
March 31, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
March 26, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Statement Regarding Recent Media Speculation
March 25, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
March 12, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Investor Conferences in March
February 25, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
February 17, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
January 13, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
December 17, 2025
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
December 15, 2025
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap